We scan new podcasts and send you the top 5 insights daily.
Chemotherapy-free or chemo-light bispecific antibody strategies demonstrate substantial clinical activity in elderly and unfit frontline diffuse large B-cell lymphoma patients. In the phase 2 MorningSun trial evaluating single-agent mosunetuzumab, patients had a median age of 82.5 years—including a patient aged 101. The chemo-free monotherapy produced a 59% complete response rate and a 69% 1-year progression-free survival rate, presenting a viable non-toxic upfront alternative.
Indefinite treatment with bispecific antibodies is likely unnecessary and exposes DLBCL patients to risks like hypogammaglobulinemia and recurrent infections. A fixed duration of no more than one year is a reasonable approach, with a readiness to stop earlier for patients in a deep, sustained complete response, potentially guided by ctDNA.
When choosing a bispecific antibody for follicular lymphoma, a major practical difference is the treatment duration. Mosunetuzumab is a time-limited therapy stopped after achieving a complete response, while Epcoritamab is given indefinitely until progression. This distinction heavily influences selection, especially for elderly patients.
Provocative data from a German study showed an 81% complete response rate in untreated, elderly DLBCL patients using a chemotherapy-free regimen of polatuzumab (an ADC), glofitamab (a bispecific), and rituximab. This challenges the decades-long R-CHOP chemotherapy backbone and points to a future of targeted frontline therapies.
For older or frail DLBCL patients who are not candidates for CAR-T cell therapy, the combination of mosunetuzumab and polatuzumab offers a potent and significantly more tolerable alternative to other bispecifics. This regimen is logistically simpler for community practice and can be used successfully even in very elderly patients.
Experts view R-mini-CHOP, the standard for older/unfit DLBCL patients, as a poor benchmark that urgently needs to be replaced. Promising chemo-free or chemo-light regimens, like the R-Polo-Glofitamab combination, are seen as the future, aiming to improve outcomes in this vulnerable population without harsh toxicities.
For DLBCL patients awaiting CAR-T cell therapy, particularly those with aggressive disease, bispecific antibodies are the preferred bridging strategy. This approach effectively controls disease and reduces tumor burden for better CAR-T outcomes, while avoiding the T-cell depleting effects of traditional chemotherapy.
An expert treating DLBCL states they no longer use bispecific antibodies as monotherapy. Combining them with partners like chemotherapy (GemOx) or ADCs (Polatuzumab) raises the complete response rate by 15-20%, offering a better chance of benefit for patients.
Early trial data for single-agent bispecific antibodies in elderly or frail patients with large cell lymphoma reveals surprisingly high efficacy. This success is prompting discussions about a chemotherapy-free future for this population, with combinations like glofitumab-polatuzumab potentially replacing traditional regimens.
In clinical practice for relapsed large cell lymphoma, glofitumab is a preferred bispecific antibody. Clinicians favor it over epcoritamab because it is time-limited (vs. indefinite treatment) and has a more patient-friendly every-three-week schedule, while also being more active than mosunetuzumab.
Long-term follow-up from the pivotal epcoritamab trial reveals that 46% of DLBCL patients who achieve a complete remission maintain it at four years. This durability provides strong evidence that bispecific monotherapy, not just CAR-T, can be a curative treatment for a subset of patients.